Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial-Reference-Cited by-同舟云学术

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial

Published:2021-10-07 Issue:12 Volume:23 Page:2775-2784
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Vaduganathan Muthiah¹^ORCID,Inzucchi Silvio E.²^ORCID,Sattar Naveed³^ORCID,Fitchett David H.⁴^ORCID,Ofstad Anne Pernille⁵,Brueckmann Martina⁶⁷,George Jyothis T.⁶,Verma Subodh⁸,Mattheus Michaela⁹,Wanner Christoph¹⁰,Zinman Bernard¹¹^ORCID,Butler Javed¹²

Affiliation:

1. Division of Cardiovascular Medicine Brigham and Womenʼs Hospital, Harvard Medical School Boston Massachusetts USA

2. Section of Endocrinology, Yale School of Medicine Yale University New Haven Connecticut USA

3. University of Glasgow Glasgow UK

4. Division of Cardiology, St. Michaelʼs Hospital University of Toronto Toronto Ontario Canada

5. Medical Department Boehringer Ingelheim KS Asker Norway

6. Boehringer Ingelheim International GmbH Ingelheim Germany

7. Faculty of Medicine Mannheim at the University of Heidelberg Mannheim Germany

8. Division of Cardiac Surgery, St. Michaelʼs Hospital University of Toronto Toronto Ontario Canada

9. Boehringer Ingelheim Pharma GmbH & Co KG Ingelheim Germany

10. Department of Internal Medicine I, Nephrology University Hospital Würzburg Würzburg Germany

11. Lunenfeld‐Tanenbaum Research Institute, Mount Sinai Hospital University of Toronto Toronto Ontario Canada

12. Department of Medicine University of Mississippi Jackson Mississippi USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14535

Reference44 articles.

1. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis

2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

3. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus

4. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

5. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis;Diabetes, Obesity and Metabolism;2024-04

2. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials;Journal of the American Heart Association;2024-03-05

3. Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines – Heart Failure Registry;Journal of Cardiac Failure;2023-09

4. Impact of diabetes duration on left ventricular mass regression with empagliflozin;ESC Heart Failure;2023-04-10

5. Insulin Independence With SGLT2 Inhibitor Use in Type 2 Diabetes;The Journal of Clinical Endocrinology & Metabolism;2023-03-22